01—Abstract
Summary
Summary of the 8-K filed September 14, 2026. Cited figures are marked; the original filing is the authoritative source.
Teva Pharmaceutical Industries Ltd. filed this Current Report on Form 8-K under Item 8.01 (Other Events, captioned Results of Operations and Financial Condition) to announce a change in how its shares trade in the United States.
On September 14, 2026, the company began trading its ordinary shares on the New York Stock Exchange in place of its American depositary shares (ADSs), under the same ticker symbol, "TEVA", that the ADSs previously used. On the same date, the Company's ADS program terminated, and each ADS was exchanged for one ordinary share. The filing states that the ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same symbol, "TEVA".
The filing contains no financial results, guidance, or other financial figures. Its significance for investors is structural: the holding unit changes from an ADS to one ordinary share, with the ticker and listing venue in the U.S. unchanged. Additional information is directed to the investor relations section of the company's website, ir.tevapharm.com.
02—Key points
Key Highlights
- Effective September 14, 2026, Teva's ordinary shares began trading on the New York Stock Exchange in lieu of American depositary shares (ADSs).
- The U.S. ticker symbol remains "TEVA", the same symbol under which the ADSs previously traded.
- The ADS program terminated on September 14, 2026, with each ADS exchanged for one ordinary share.
- The ordinary shares continue to trade on the Tel Aviv Stock Exchange under the symbol "TEVA".
- The filing reports no financial results, financial condition figures, or guidance.
- Additional information is available at the company's investor relations website, ir.tevapharm.com.
03—Questions
Frequently Asked Questions
What changed for Teva shareholders on September 14, 2026?
Teva's ordinary shares began trading on the New York Stock Exchange in place of its American depositary shares, and the ADS program terminated. Each ADS was exchanged for one ordinary share.
Did the ticker symbol change?
No. The ordinary shares trade on the New York Stock Exchange under the same ticker symbol, "TEVA", that the ADSs previously used.
Does this change affect the company's Tel Aviv listing?
The filing states that the ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same symbol, "TEVA".
Does this filing include financial results or guidance?
No. The filing is an Item 8.01 report about the change in the form of U.S. trading and does not include financial results, financial condition figures, or guidance.
Where can investors find more information?
The filing directs investors to the investor relations section of the company's website, ir.tevapharm.com.
04—Continue